Indeed, for the patient carrying the p.T599dup mutation, a liquid biopsy approach was available, demonstrating that longitudinal monitoring of the BRAF mutant allele fraction by liquid biopsy is a useful tool to identify tumor progression and track disease evolution. This evidence concerns the gene BRAF and neoplasm.